|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One UP tumor had oncogenic mutations in FGFR3, PIK3CA, and the TERT promoter, and arose in a patient with recurrent non-invasive papillary urothelial carcinomas.
|
30838648 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found TERT promoter mutations in 77% of low-grade noninvasive papillary carcinomas, with a relatively lower incidence of 65% in high-grade noninvasive papillary carcinomas and carcinomas in situ; p = 0.017.
|
31028363 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Chondroid-matrix producing carcinomas lacked PI-3 kinase and Ras-Map kinase aberrations and TERT promoter mutations, compared to 100%, 39%, and 39% of non-matrix-producing tumors, respectively.
|
29946183 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A recent study investigating TERT promoter mutations in ovarian carcinomas found C228T and C250T mutations in 15.9% of clear cell carcinomas.
|
29449679 |
2018 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.
|
28052688 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our group and others have previously demonstrated the presence of TERT promoter mutations (TERT-mut) in 60-80% of urothelial carcinomas and some of their histologic variants.
|
28597078 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No mutations were observed in the TERT promoter region in BTs and TCCs, which is mutated in about 50%-75% of urothelial carcinoma and in 16% of ovarian clear-cell carcinomas.
|
28639280 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations occur at a higher rate than that seen in PTC in general and may help explain the aggressive behavior of these histologically deceptive primary carcinomas.
|
28049366 |
2017 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Further analyses showed that the AC variant conferred a lower risk for early stage UTUCs or those with a wt TERT promoter.
|
26934125 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations (TERT-mut) are detectable in the majority of urothelial carcinomas.
|
26965579 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations have been recently described (and associated with distant metastases and reduced survival) in papillary and follicular carcinomas, as well as in poorly differentiated and undifferentiated carcinoma.
|
26510840 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations in periocular carcinomas: implications of ultraviolet light in pathogenesis.
|
26472403 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations (TERT-mut) have been detected in 60% to 80% of urothelial carcinomas.
|
26980028 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A better understanding of the prognostic role of TERTp mutation (together with additional ones like BRAF, RAS, PIK3CA, AKT1, or TP53) and the clarification of their putative role in fine-needle aspiration biopsies are likely to allow, in the future, an early refinement of the stratification risk in patients with well-differentiated carcinomas.
|
28231576 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, none of the remaining cases (total 65 cases of benign lesions, PAUB, and metastatic carcinomas) was positive for TERT promoter mutation.
|
26239299 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found that TERT promoter mutations were present in 21% (3/14) of endometrial clear cell carcinomas and 16% (9/56) of ovarian clear cell carcinomas.
|
25081752 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
|
24742867 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
|
24141777 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found that the frequencies of somatic mutations in the TERT promoter varied substantially between different types of urogenital tumors (range: 0-63.7%), with urothelial carcinomas showing the highest mutation frequency and prostate cancer showing no mutation.
|
24215939 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutation tended to be mutually exclusive with loss of ARID1A protein expression (p = 4.4 × 10(-9) ) and PIK3CA mutation (p = 0.0019) in ovarian clear cell carcinomas.
|
24338723 |
2014 |
|
LOC110806263
|
0.100 |
Biomarker
|
group |
BEFREE |
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
|
25474136 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas.
|
24476079 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To explore their role in bladder cancer development and to assess their utility as urine markers for early detection, we sequenced the TERT promoter in 76 well-characterized papillary and flat noninvasive urothelial carcinomas, including 28 pTa low-grade transitional cell carcinomas (TCC), 31 pTa high-grade TCCs, and 17 pTis carcinoma in situ lesions.
|
24121487 |
2013 |